

involved in the response. The number of samples tested during a response to a possible event could range from 10,000 to more than 500,000 samples depending on the length and breadth of the event. Since there is potentially a

large range in the number of samples for a surge event, CDC estimates the annualized burden for this event will be 2,250,000 hours or 625 responses per respondent.

There is no cost to the respondents other than their time. The total estimated annualized burden is 2,382,300 hours.

## ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Avg. burden per response (in hrs)
Public Health Laboratories .....	Biennial Requalification .....	150	1	2
Public Health Laboratories .....	General Surveillance Testing Results .....	150	25	24
Public Health Laboratories .....	Proficiency Testing/Validation Testing Results.	150	5	56
Public Health Laboratories .....	Surge Event Testing Results .....	150	625	24

Dated: February 26, 2013.

**Ron A. Otten,**

*Director, Office of Scientific Integrity (OSI), Office of the Associate Director for Science (OADS), Office of the Director, Centers for Disease Control and Prevention.*

[FR Doc. 2013-04900 Filed 3-1-13; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Agency Recordkeeping/Reporting Requirements Under Emergency Review by the Office of Management and Budget (OMB)

*Title:* TANF Quarterly Financial Report, ACF-196.

*OMB No.:* 0970-0247.

*Description:* This information collection is authorized under Section 411(a)(3) of the Social Security Act. This request is for revision of approval to use the Administration for Children and Families' (ACF) 196 form for periodic

financial reporting under the Temporary Assistance for Needy Families (TANF) program. States participating in the TANF program are required by statute to report financial data on a quarterly basis. This form meets the legal standard and provides essential data on the use of Federal funds. Failure to collect the data would seriously compromise ACF's ability to monitor program expenditures, estimate funding needs, and to prepare budget submissions required by Congress. Financial reporting under the TANF program is governed by 45 CFR part 265. This renewal restores columns for reporting Emergency Contingency Fund and Supplemental Grant expenditures.

*Respondents:* TANF Agencies.

## ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
ACF-196 .....	51	4	10	2040

Estimated Total Annual Burden Hours: 2040.

#### Additional Information

ACF is requesting that OMB grant a 180 day approval for this information collection under procedures for emergency processing by March 15, 2013. A copy of this information collection, with applicable supporting documentation, may be obtained by emailing the Administration for Children and Families, Reports Clearance Officer: [rsargis@acf.hhs.gov](mailto:rsargis@acf.hhs.gov).

Comments and questions about the information collection described above should be directed to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for ACF, Office of Management and Budget, Paperwork Reduction Project; 725 17th Street NW.,

Washington, DC 20503; FAX: (202) 395-7285; email:

[oir\\_submission@omb.eop.gov](mailto:oir_submission@omb.eop.gov).

**Robert Sargis,**

*Reports Clearance Officer.*

[FR Doc. 2013-04826 Filed 3-1-13; 8:45 am]

**BILLING CODE 4184-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2012-P-1071]

#### Determination That GERE (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GERE (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) has determined that GERE (Sermorelin Acetate)